Programmed death-1 (PD-1), also know as CD279 is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Like the clones RMP1-14 and J43 antibodies, the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo.
Catalog | IV0107 |
Product Name | InVivoPro Anti-Mouse PD-1(CD279) in vivo antibody, Clone 29F.1A12 |
Size | 1mg/5mg/25mg/50mg/100mg |
Isotype | Rat IgG2a |
Clone | 29F.1A12 |
Target | PD-1 |
Other Names | Programmed Death-1, CD279, PD-1 |
Isotype Control Catalog Code | IV0105 or Rat IgG2a Isotype Control |
Dilution Buffer | PBS, pH 7.2, contains no stabilizers or preservatives |
Reactivity | Mouse |
Host Species | Rat |
How much antibody to use in vivo | 200-500 μg per mouse; or 10 mg/kg. This range is based off the most recent publication data using the 29F.1A12 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications. |
Background(ichorbio) | Programmed death-1 (PD-1), also know as CD279 is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Like the clones RMP1-14 and J43 antibodies, the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo. |
Applications | In vivo blocking of PD-1/PD-L signaling, Flow cytometry, Immunohistochemistry(Frozen), Western blot |
Purification | protein A or G |
Storage | This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles. |
Shipping | 2-8°C with blue ice |
Concentration | Lot specific, generally ≥ 5.0 mg/ml |
Shelf Life | 12 months from the date of receipt if stored as recommended |
Formulation | PBS Buffer, PH 7.2, with no carrier protein, or preservatives. |
Sterility | 0.2 μM filtered |
Endotoxin | ≤ 1.0 EU/mg, by the LAL method |
Purity | 99% |
Sade-Feldman, Moshe et al. "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma",Cell 175.4 (2018): 998-1013.e20.
Zhang, Lei et al. "Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer",Cell 181.2 (2020): 442-459.e29.
Soula, Mariluz et al. "Glycosphingolipid Synthesis Mediates Immune Evasion in KRAS-driven Cancer",Nature 633.8029 (2024): 451-458.